
Claims


1. A compound of formula I or, ~~its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N oxides,~~ its pharmaceutically acceptable salts~~, its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals~~,




(I)

wherein, in the compound of formula I,

R^A is independently selected at each occurrence from-



, such that at least once it is selected as



Ring 'A' is selected from 3 to 6 membered carbocycle and 3 to 6 membered heterocycle, the ring 'A' may further be annulated with substituted- or unsubstituted- carbocycle, substituted- or unsubstituted- heterocycle, substituted- or unsubstituted- aromatic carbocycle or substituted- or unsubstituted- aromatic heterocycle;

ring D is selected from substituted- or unsubstituted- 5 to 10 membered carbocycles, substituted- or unsubstituted- 5 to 10 membered heterocycles containing 1 to 3 heteroatoms/groups selected from $N(R^{10})$, $S(O)_p$, O or

C(=O), substituted- or unsubstituted- aromatic carbocycle, and 5 to 6 membered substituted- or unsubstituted- aromatic heterocycle containing heteroatoms selected from N, S or O;

Ring 'E' is 5 to 10 membered heterocycle, the ring 'E' may be monocyclic, fused bicyclic, bridged bicyclic or spiro bicyclic;

R^1 is selected independently at each occurrence from the group consisting of halogen, substituted- or unsubstituted- C_{1-6} alkyl, $R^{10}O$-, $R^{10a}OC(=O)$-, and $(R^{10})(R^{11})NC(=O)$-; or two R^1s taken together may form an oxo (=O) group;

R^2 is selected independently at each occurrence from the group consisting of substituted- or unsubstituted- C_{1-6} alkyl, $R^{10a}C(=O)$-, $R^{10a}SO_2$-, $R^{10a}OC(=O)$-, $R^{10}(R^{11})NC(=O)$-, $R^{10a}OC(=O)N(R^{11})C(R^a)(R^b)C(=O)$-, $R^{10a}OC(=O)N(R^{11})C(R^a)(R^b)C(R^c)(R^d)C(=O)$-, $R^{10}(R^{11})NC(=O)N(R^{12})C(R^a)(R^b)C(=O)$-, $R^{10}(R^{11})NC(=O)N(R^{12})C(R^a)(R^b)C(R^c)(R^d)C(=O)$-, $R^{10a}SO_2N(R^{11})C(R^a)(R^b)C(=O)$-, $R^{10a}SO_2N(R^{11})C(R^a)(R^b)C(R^c)(R^d)C(=O)$-, and $R^{10a}OC(=O)N(R^{11})C(R^a)(R^b)SO_2$-;

R^3 is selected from O and $N(R^{13})$;

R^4 is selected independently at each occurrence form $CR^a(R^b)$, O, $N(R^{13})$, C(=O), $S(O)_p$, substituted- or unsubstituted carbocycle, substituted- or unsubstituted- heterocycle, substituted- or unsubstituted- arylene and substituted- or unsubstituted- heteroarylene, wherein, substitutions on carbocycle, heterocycle, arylene, and heteroarylene are selected from the group consisting of halogen, substituted- or unsubstituted- C_{1-6} alkyl, and alkyl-O-;

R^5 is selected from hydrogen and substituted- or unsubstituted- alkyl;

R^6 and R^7 are independently selected from the group consisting of hydrogen, halogen, substituted- or unsubstituted- C_{1-6} alkyl, and $R^{10}O$-;

R^8 is selected from hydrogen and C_{1-6} alkyl;

R^9 is selected from the group consisting of hydrogen, C_{1-6} alkyl, $R^{10a}C(=O)$-, $R^{10a}SO_2$-, $R^{10a}OC(=O)$-, $(R^{10})(R^{11})NC(=O)$-, $R^{10a}OC(=O)N(R^{11})CR^a(R^b)C(=O)$-, $R^{10a}OC(=O)N(R^{11})CR^a(R^b)C(R^c)(R^d)C(=O)$-, $R^{10}(R^{11})NC(=O)N(R^{12})CR^a(R^b)C(=O)$-,

$R^{10}(R^{11})NC(=O)N(R^{12})CR^a(R^b)C(R^c)(R^d)C(=O)$-, $R^{10a}SO_2N(R^{11})CR^a(R^b)C(=O)$-, $R^{10a}SO_2N(R^{11})CR^a(R^b)C(R^c)(R^d)C(=O)$-, and $R^{10a}OC(=O)N(R^{11})CR^a(R^b)SO_2$-;

R^{10}, R^{11}, R^{11a} and R^{12} are independently selected from hydrogen and substituted- or unsubstituted- C_{1-6} alkyl;

R^{10a} is substituted- or unsubstituted- C_{1-6} alkyl;

R^{13} is selected from hydrogen and substituted- or unsubstituted- alkyl group;

R^a, R^b, R^c and R^d, are independently selected from hydrogen, halogen, substituted- or unsubstituted- C_{1-6} alkyl, substituted- or unsubstituted- aryl, substituted- or unsubstituted- heteroaryl, substituted- or unsubstituted- cycloalkyl, and substituted- or unsubstituted- heterocyclyl, or R^a, R^b, R^c and R^d together with the carbon atom(s) to which they are attached forming substituted- or unsubstituted- carbocycle, substituted- or unsubstituted- heterocycle;

m is an integer ranging between 0 to 2, selected independently at each occurrence;

n is an integer ranging between 0 and 2;

p is an integer ranging between 0 and 2;

when n = 2 and R^4 is selected as $CR^a(R^b)$ for both the occurrences, two R^as together can form a bond to form a alkenylene linkage or two R^as and two R^bs together can form bonds to form alkynylene linkage;

'alkyl' may be substituted with 1 to 4 substituents selected from the group consisting of oxo, halogen, cyano, aryl, hereroaryl, cycloalkyl, heterocyclyl, (alkyl)C(=O)-, (alkyl)SO_2-, $R^{14a}O$-, (alkyl)OC(=O)-, (alkyl)C(=O)O-, $(R^{14})(H)NC(=O)$-, (R^{14})(alkyl)NC(=O)-, (alkyl)C(=O)N(H)-, $R^{14}(H)N$-, R^{14}(alkyl)N-, $R^{14}(H)NC(=O)N(H)$-, and R^{14}(alkyl)NC(=O)N(H)-;

'cycloalkyl' and 'carbocycle' may be substituted with 1 to 2 substituents selected from the group consisting of oxo, halogen, C_{1-6} alkyl, haloalkyl, (alkyl)C(=O)-, (alkyl)SO_2-, $R^{14a}O$-, (alkyl)OC(=O)-, (alkyl)C(=O)O-,

$R^{14}(H)NC(=O)$-, $R^{14}(alkyl)NC(=O)$-, $(alkyl)C(=O)N(H)$-, $R^{14}(H)N$-, $R^{14}(alkyl)N$-, $R^{14}(H)NC(=O)N(H)$-, and $R^{14}(alkyl)NC(=O)N(H)$-;

'aryl' or 'aromatic carbocycle', may be substituted with 1 to 2 substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, C_1 to C_6 alkyl, perhaloalkyl, alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H_2N-, alkyl-SO_2-, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, $H_2NC(=O)$-, alkyl-N(alkyl)SO_2-, alkyl-N(H)SO_2-, H_2NSO_2-;



'heteroaryl' or 'aromatic heterocycle' may be substituted with 1 to 2 substituents selected from the group consisting of halogen, nitro, cyano, hydroxy, C_1 to C_6 alkyl, perhaloalkyl, alkyl-O-, perhaloalkyl-O-, alkyl-N(alkyl)-, alkyl-N(H)-, H_2N-, alkyl-SO_2-, alkyl-C(=O)N(alkyl)-, alkyl-C(=O)N(H)-, alkyl-N(alkyl)C(=O)-, alkyl-N(H)C(=O)-, $H_2NC(=O)$-, alkyl-N(alkyl)SO_2-, and alkyl-N(H)SO_2-, H_2NSO_2-;


ring carbons of 'heterocyclyl' and 'heterocycle' may be substituted with 1 to 2 substituents selected from the group consisting of oxo, halogen, alkyl, $R^{14a}O$-, $(alkyl)OC(=O)$-, $(alkyl)C(=O)O$-, $R^{14}(H)NC(=O)$-, $R^{14}(alkyl)NC(O)$-, $(alkyl)C(=O)N(H)$-, $R^{14}(H)N$-, $R^{14}(alkyl)N$-, $R^{14}(H)NC(=O)N(H)$-, and $R^{14}(alkyl)NC(=O)N(H)$-; the substituents on ring nitrogen(s) of 'heterocyclyl' and 'heterocycle' are selected from the group consisting of alkyl, $(alkyl)C(=O)$-, $(alkyl)SO_2$-, $(alkyl)OC(=O)$-, $R^{14}(H)NC(=O)$-, $R^{14}(alkyl)NC(=O)$-;

R^{14} is selected from hydrogen and alkyl;

R^{14a} is selected from hydrogen, alkyl, perhaloalkyl.

2. The compound of formula I or~~,~~ ~~its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N oxides,~~ its pharmaceutically acceptable salts, ~~its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals,~~ as claimed in claim 1, wherein R^A is selected independently at each occurrence from -

 and ,

where, ring A is 3 to 6 membered carbocycle, such that at least once it is selected as .

3. The compound of formula I or ~~, its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N-oxides,~~ its pharmaceutically acceptable salts, ~~its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals,~~ as claimed in any one of claims 1 and 2, wherein R^3 is selected as NH.

4. The compound of formula I or ~~, its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N-oxides,~~ its pharmaceutically acceptable salts, ~~its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals,~~ as claimed in any one of claims 1-3, wherein R^4 is selected from phenylene and five membered heteroarylene containing 1 or 2 heteroatoms selected from N and S, when n is selected as 1.


5. The compound of formula I or~~,~~ ~~its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N-oxides,~~ its pharmaceutically acceptable salts, ~~its polymorphs, its solvates, its optical isomers,~~ its clathrates or its co-crystals, as claimed in any one of claims 1-3, wherein R^4 is selected as CR^aR^b, when n is selected as 2 to form an ethylene or ethynylene linkage.

6. The compound of formula I or, its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals, as claimed in any one of claims 1-5, wherein n is selected from 0, 1 and 2.


7. The compound of formula I or, its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals, as claimed in any one of claims 1-6, wherein R^5, R^6 and R^7 are selected as hydrogen.

8. The compound of formula I or, its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals, as claimed in any one of claims 1-7, wherein Ring D is selected from the group consisting of aromatic carbocycle, six membered carbocycle, seven membered carbocycle, and seven membered heterocycle containing one heteroatom particularly selected as oxygen.


9. The compound of formula I or, its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N oxides, its pharmaceutically acceptable salts, its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals, as claimed in any one of claims 1-8, wherein, R^A is selected independently at each occurrence from -



and



,

where, ring A is 3 to 6 membered carbocycle, such that at least once it is selected as  ; R^3 is selected as NH; R^4 is selected from the group consisting of CR^aR^b, phenylene and five membered heteroarylene containing 1 or 2 heteroatoms selected from N and S; n is selected from 0, 1 and 2; R^5, R^6 and R^7 are selected as hydrogen; and Ring D is selected from the group consisting of aromatic carbocycle, six membered carbocycle, seven membered carbocycle, and seven membered heterocycle containing one heteroatom particularly selected as oxygen.

10. The compound of formula I or ~~, its tautomeric forms, its stereoisomers, its analogues, its prodrugs, its isotopically substituted analogues, its metabolites, its sulfoxides, its N-oxides,~~ its pharmaceutically acceptable salts, ~~its polymorphs, its solvates, its optical isomers, its clathrates or its co-crystals,~~ as claimed in any one of claims 1-9, wherein the compound is selected from the group consisting of:

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1,4,5,6-

tetrahydrobenzo[3,4]cyclohepta[1,2-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1,4,5,6-tetrahydrobenzo[3,4]cyclohepta[1,2-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopropyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1,4,5,6-tetrahydrobenzo[3,4]cyclohepta[1,2-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopropyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1,4,5,6-tetrahydrobenzo[3,4]cyclohepta[1,2-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-N-ethyl-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-N,3-dimethylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-N,3-dimethylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-(1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)cyclopentyl)-1H-

benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(4-(2-(1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)cyclohexyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)phenyl)-1H-benzo[d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-(1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)cyclohexyl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-(1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)cyclohexyl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(5-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-naphtho[1,2-d]imidazol-7-yl)thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(5-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-((2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)ethynyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(6-(2-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-7-yl)ethyl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(5-(5-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-8-yl)thiazol-2-yl)-1H-benzo[d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclopentyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(7-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(7-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-1H-naphtho[1,2-d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(7-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-naphtho[1,2-d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide;

(S)-2-(methoxycarbonyl)amino-N-(1-(7-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)phenyl)-1H-naphtho[1,2-d]imidazol-2-yl)cyclohexyl)-3-methylbutanamide; and

(S)-2-(methoxycarbonyl)amino-N-(1-(8-(4-(2-((S)-1-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-

benzo[d]imidazol-6-yl)phenyl)-4,5-dihydro-1H-benzo[2,3]oxepino[4,5-d]imidazol-2-yl)cyclobutyl)-3-methylbutanamide.

11. A pharmaceutical composition comprising a compound or a combination of compounds according to any one of claims 1-10 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.

12. ~~A method of~~A pharmaceutical composition to inhibit~~ing~~ the replication of an RNA-containing virus comprising contacting said virus with a therapeutically effective amount of a compound or combination of compounds of any one of claims 1-10, or a pharmaceutically acceptable salt thereof.

13. ~~A method of~~A pharmaceutical composition for treating or preventing infection caused by an RNA-containing virus comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or combination of compounds of any one of claims 1-10, or a pharmaceutically acceptable salt thereof.

14. The ~~method~~ pharmaceutical composition in~~of~~ claim 12, wherein the RNA-containing virus is hepatitis C virus.

15. The ~~method of~~use according to claim 12, further comprising the step of co-administering one or more agents selected from the group consisting of a host immune modulator and an antiviral agent, or a combination thereof.

16. The ~~method~~ use of claim 14, wherein the host immune modulator is selected from the group consisting of interferon-alpha, pegylated-interferon-alpha, interferon-beta, interferon-gamma, consensus interferon, a cytokine, and a vaccine.

17. The ~~method~~ use of claim 14, wherein the antiviral agent inhibits replication of HCV by inhibiting host cellular functions associated with viral replication.

18. The ~~method~~ use of claim 14, wherein the antiviral agent inhibits the replication of HCV by targeting proteins of the viral genome.

19. The ~~method~~ use of claim 14, wherein said antiviral agent is an inhibitor of a HCV viral protein, a replication process or a combination thereof, wherein

said targeting protein or replication process is selected from the group consisting of helicase, protease, polymerase, metalloprotease, NS4A, NS4B, NS5A, assembly, entry, and IRES.

20. The ~~method~~ use of claim 12, further comprising the step of co-administering an agent or combination of agents that treat or alleviate symptoms of HCV infection selected from cirrhosis and inflammation of the liver.

21. The ~~method~~ use of claim 12, further comprising the step of co-administering one or more agents that treat patients for disease caused by hepatitis B (HBV) infection.

22. The ~~method~~ use of claim 12, further comprising the step of co-administering one or more agents that treat patients for disease caused by human immunodeficiency virus (HIV) infection.

23. The pharmaceutical composition of claim 11, further comprising an agent selected from interferon, pegylated interferon, ribavirin, amantadine, an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, or an internal ribosome entry site inhibitor.

24. The composition of claim 11, further comprising a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof.

25. A ~~method of~~pharmaceutical composition for treating hepatitis C infection in a subject in need thereof comprising co-administering to said subject a cytochrome P450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof, and a compound of any one of claims 1-10 or a pharmaceutically acceptable salt thereof.